Agilent Technologies Inc is trading 7.5% up at $140.35 in pre-market action, significantly outperforming the broader market due to several recent positive catalysts. - The company reported strong Q2 2026 earnings on May 27, beating estimates for EPS and revenue, and raising its FY 2026 EPS guidance. - Agilent received FDA approval for expanded use of its PD-L1 diagnostic in multiple cancer types on June 2, 2026. - On June 3, 2026, Agilent announced a collaboration with OpenAI and Boston Consulting Group to accelerate AI deployment.